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Insulin degludec and insulin glargine 300 U/
mL: Which of these two insulins causes less
hypoglycemia?
The interesting article by Yamabe et al.1
showed, using continuous glucose moni-
toring, that insulin degludec (I-Deg) was
associated with a high percentage of time
with nocturnal hypoglycemia than with
insulin glargine 300 U/mL (I-G300;
P = 0.02). However, we observe that
some possible confounding factors might
have influenced the results, such as dif-
ferences in concomitant medications, use
of the same titration protocol for both
kinds of insulin or differences in glucose
levels. This is also a recurrent problem in
clinical trials, which sometime produce
conflicting results. In fact, the study of
Yamabe et al. is partly in agreement with
some recently published clinical trials
that gave different conclusions. In the last
months of 2018, three studies2–4 com-
pared I-Deg with I-G300 using different
approaches, but their conclusions were
quite different, especially regarding the
possibility of inducing hypoglycemia.
In Clinical Outcome Assessment of
the Effectiveness of Insulin Degludec in
Real-life Medical Practice (CONFIRM)3,
a real-world study, the use of I-Deg ver-
sus I-G300 was associated with a lower
risk of hypoglycemia. Surprisingly, the
other two recent comparative studies,
Differentiate Gla-300 clinical and Eco-
nomic in Real-World Via EMR (DELI-
VER)3 and BRIGHT4, led to opposite
conclusions (Table 1). CONFIRM and
DELIVER had very different study
designs (one above all, was the insulin
naive vs switch procedure); in both stud-
ies the basal glycated hemoglobin was
high, and most participants did not
achieve the optimal glucose control, all
conditions that make it difficult to made
an adequate assessment of the risk of
hypoglycemia. In contrast to CONFIRM,
DELIVER also included hypoglycemic
events observed in the emergency depart-
ment. The reliability in reporting hypo-
glycemic events is another important
confounding factor, especially in real-
world evidence studies. Regarding the
BRIGHT study, it was found that the risk
of hypoglycemia was slightly, but signifi-
cantly, higher with the use of I-Deg than
with I-G300, especially during the phase
of titration (hypoglycemia ≤70 mg/dL:
+2.39 events per patient-year, P = 0.02;
hypoglycemia ≤54 mg/dL: +0.37 events
per patient-year, P = 0.04). However,
according to the data presented in table
1 of reference 4 of the BRIGHT study
(significance level was not reported), the
two groups were not comparable. In fact,
applying the Student’s t-test for unpaired
data, we observed that patients allocated
to the I-Deg group had significantly
(P < 0.01) lower glycated hemoglobin
values than those of the I-G300 group
(8.57 vs 8.71%), but also significantly
(P < 0.01) lower fasting plasma glucose
concentrations (182 vs 191 mg/dL) and
self-monitoring plasma glucose (172 vs
178 mg/dL; P < 0.05). Also, the authors
reported that by using fewer units of I-
Deg (0.43 units/kg) than I-G300
(0.54 units/kg), fasting plasma glucose
concentrations were more reduced in the
I-Deg group, with a significant difference
of 7.68 mg/dL, versus the I-G300 group.
These results would suggest that I-Deg
probably has a pronounced hypoglycemic
power. Another important confounding
factor is the different use of concomitant
medications between the studies, in par-
ticular that of secretagogues, such as sul-
fonylureas. Given the different direct and
indirect (mainly due to hypoglycemia)
costs of I-Deg and I-G300, it is impor-
tant to clarify these controversial aspects.
In conclusion, we believe that either
head-to-head randomized controlled tri-
als or real-world studies need to be
designed including well-matched groups,
paying special attention to potential con-
founding factors. Otherwise, the risk is to
prove everything and nothing.
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Table 1 | Characteristics of the three studies that compared insulin degludec versus insulin glargine 300 U/mL
BRIGHT DELIVER CONFIRM
Study design RCT RW, propensity matched RW, propensity matched
Participants (n) 463 (I-G300) vs 466 (I-Deg) 1,592 vs 1,592 2,028 vs 2,028
T2D patients Insulin naive Switch from I-G100 or
I-Det to I-G300 or I-Deg
Insulin naive
Use of sulphonylureas (%) ~65 ~25 ~25
Basal HbA1c (%) 8.71 – 0.83 (I-G300) 9.1 – 1.8 (I-G300)* 9.6 – 2.2 (I-G300)**
8.57 – 0.80 (I-Deg) 9.1 – 1.9 (I-Deg)* 9.5 – 2.1 (I-Deg)**
P < 0.001 P = NS P = NS
FPG (mg/dL) 191 – 49 (I-G300) NA NA
182 – 51 (I-Deg)
P < 0.001
SMPG (mg/dL) 178 – 40 (I-G300) NA NA
172 – 38 (I-Deg)
P < 0.001
Insulin efficacy I-Deg better than
I-G300 (~20% fewer units of I)
I-Deg similar to I-G300 I-Deg better than I-G300
Incidence of hypoglycemia I-Deg > I-G300 (titration phase) I-Deg > I-G300
(event rate PPY: 0.08 vs 0.05; P = 0.016)
I-Deg < I-G300 (–30% risk)
Sponsor Sanofi Sanofi NovoNordisk
Data presented as the mean – standard deviation. Statistical comparison between studies and for data of the BRIGHT study was carried out using
the Student’s unpaired t-test: *P < 0.001 versus BRIGHT; **P < 0.001 versus Differentiate Gla-300 clinical and Economic in Real-World Via EMR (DELI-
VER) and BRIGHT. CONFIRM, Clinical Outcome Assessment of the Effectiveness of Insulin Degludec in Real-life Medical Practice; FPG, fasting plasma
glucose; G, glargine; HbA1c, glycated hemoglobin; I-Deg, insulin degludec; I-Det, Det, insulin detemir; I-G300, glargine 300 U/mL; NA, not available;
NS, not significant; PPY, per person-year; RCT, randomized controlled trial; RW, real-world; SMPG, self-monitoring plasma glucose; T2D, type 2 dia-
betes.
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